Exploring The Clinical Efficacy Of Self-formulated Shugan Lipi Decoction On Ulcerative Colitis With Liver Depression And Spleen Deficiency Based On Brain-gut Axis Theory

Objective:Exploring the clinical efficacy of self-formulated Shugan Lipi decoction on ulcerative colitis with liver depression and spleen deficiency based on brain-gut axis theory,and observe the safety and recurrence rates,to provide the basis for clinical treatment of ulcerative colitis and broaden the treatment of ideas.Methods:Sixty-four patients with ulcerative colitis who met the study criteria were collected from the Affiliated Hospital of Jiangxi University of Chinese Medicine and randomly divided into 32 patients in the treatment group and 32 patients in the control group.The control group were treated with Mesalazine enteric-coated tablets alone orally,while the treatment group were treated with a combination of Chinese and Western medicine,using Mesalazine in combination with the tutor’s experienced prescription(self-formulated Shugan Lipi decoction)orally.After 8weeks of treatment,the efficacy and safety were assessed by statistical analysis of the observed items(TCM syndrome score,modified Mayo score,brain-gut peptides indexes and anxiety and depression scores,safety indicators,etc).Patients who went into remission were also followed up for 3 months to observe recurrence in both groups.Results:During this study,there were 2 cases in the treatment group and 2 cases in the control group who met the shedding and exclusion criteria,so the final inclusion in the statistical analysis was 30 cases in the treatment group and 30 cases in the control group.1.Comparison of general data: After comparing the two groups in terms of gender,age,duration of disease,extent of lesions and severity of disease,the data was found to be comparable between the two groups(p> 0.05).2.Comparison of TCM syndrome scores: Both groups had comparable TCM syndrome scores before treatment(p > 0.05);After treatment,both groups showed improvement in their TCM syndrome scores,and the treatment group showed better improvement in clinical symptoms compared to the control group(p<0.05).3.Comparison of modified Mayo scores: Before treatment,Mayo scores and Mayo endoscopic sub-scores were comparable between the two groups(p>0.05);after treatment,all these scores decreased,and the decrease was greater in the treatment group than in the control group(p<0.05).4.Comparison of brain-gut peptides indexes: Before treatment,serum 5-HT,VIP and SP levels were comparable between the two groups(p>0.05);after treatment,5-HT and SP levels showed a decreasing trend in both groups,and the treatment group showed a greater decrease than the control group(p<0.05),VIP levels showed an increasing trend,and the increase was greater in the treatment group(p<0.05).5.Comparison of anxiety and depression scores: Before treatment,HAMA and HAMD scores were comparable between the two groups(p>0.05);after treatment,HAMA and HAMD scores decreased in both groups,and the decrease was greater in the treatment group(p<0.05).6.Comparison of clinical efficacy:According to statistical analysis,the clinical effective rate(93.33%)and clinical remission rate(66.67%)in the treatment group were significantly greater than those in the control group(clinical effective rate 73.33%,clinical remission rate 36.67%)(p < 0.05).7.Comparison of TCM syndrome efficacy: The total effective rate of the treatment group was 93.33% significantly greater than that of the control group,which was 73.33%(p < 0.05).8.Comparison of mucosal healing rate: The healing rate of mucosa in the treatment group was 56.67%,which was significantly higher than 26.67% in the control group(p<0.05).9.Comparison of long-term efficacy: The 3-month recurrence rate in the treatment group was 5.00%,which was significantly lower than that in the control group(36.36%)(p<0.05).10.Safety evaluation: No significant liver and kidney damage and serious adverse reactions and complications were observed in both groups,who have also not experienced a reversal of their condition and need to switch to other treatment options.only some patients experienced mild adverse reactions such as nausea and vomiting,headache and dizziness,and the incidence of adverse reactions was not statistically significant(p>0.05).Conclusions:1.Self-formulated Shuganlipi Decoction combined with mesalazine was significantly better than mesalazine group in improving clinical symptoms and reducing disease activity in patients with ulcerative colitis.2.Self-formulated Shuganlipi Decoction combined with mesalazine can significantly regulate brain-gut peptides 5-HT,VIP and SP levels,while relieving anxiety and depression.3.Self-formulated Shuganlipi Decoction combined with mesalazine can significantly promote mucosal healing in ulcerative colitis and significantly improve clinical efficacy,while showing a lower recurrence rate and safe and reliable drug administration.4.Self-formulated Shuganlipi Decoction combined with mesalazine may exert its effect on the treatment of UC by regulating the function of the brain-gut axis.